Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives $66.00 Consensus Target Price from Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have been given an average rating of “Buy” by the eleven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $66.00.

A number of research firms have recently issued reports on MAZE. Truist Financial dropped their price target on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. JPMorgan Chase & Co. increased their target price on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, March 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th.

Maze Therapeutics Stock Down 0.0%

Shares of NASDAQ MAZE opened at $27.68 on Friday. Maze Therapeutics has a 52-week low of $12.81 and a 52-week high of $53.65. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -10.94 and a beta of 2.14. The stock has a 50 day moving average price of $27.10 and a 200 day moving average price of $34.46. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. Sell-side analysts expect that Maze Therapeutics will post -2.73 earnings per share for the current year.

Insider Transactions at Maze Therapeutics

In other news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $28.02, for a total transaction of $210,150.00. Following the transaction, the insider directly owned 26,250 shares in the company, valued at approximately $735,525. This trade represents a 22.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the transaction, the chief executive officer directly owned 23,337 shares in the company, valued at approximately $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 141,470 shares of company stock valued at $3,887,939. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Maze Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada raised its position in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Maze Therapeutics during the 4th quarter worth $39,000. Ameritas Investment Partners Inc. boosted its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Maze Therapeutics during the fourth quarter valued at about $43,000. Finally, Russell Investments Group Ltd. grew its stake in Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.